En savoir plus sur le livre
In the 1960s, it was reported that interferons have antitumour activity in different experimental models. Since that time, numerous studies have been performed to elucidate the various mechanisms of action that have been proposed. However, there is much controversy in the literature and promising preclinical findings failed to translate into substantial clinical progress. The present book gives a critical overview of current knowledge of how interferons act in solid tumours. For this purpose, after two chapters of general aspects of interferon action and interaction, selected solid tumours which are commonly considered difficult to treat in advanced stages are discussed with respect to both preclinical data and clinical experience.
Achat du livre
Biological Modulation of Solid Tumours by Interferons, Karl Pummer, U. Veronesi
- Langue
- Année de publication
- 1994
- Reliure
- (rigide),
- État du livre
- Bon
- Prix
- 103,99 €
Modes de paiement
Personne n'a encore évalué .
- Titre
- Biological Modulation of Solid Tumours by Interferons
- Langue
- Anglais
- Auteurs
- Karl Pummer, U. Veronesi
- Éditeur
- Springer
- Publié
- 1994
- Format
- rigide
- Pages
- 75
- ISBN10
- 3540577645
- ISBN13
- 9783540577645
- Séries
- Catégories
- Mots clés
- Médecine, Littérature spécialisée, Recherche, Cancer, tumeurs, Fondements, Oncologie, Immunologie, Cancer du sein, Recherche médicale
- Description
- In the 1960s, it was reported that interferons have antitumour activity in different experimental models. Since that time, numerous studies have been performed to elucidate the various mechanisms of action that have been proposed. However, there is much controversy in the literature and promising preclinical findings failed to translate into substantial clinical progress. The present book gives a critical overview of current knowledge of how interferons act in solid tumours. For this purpose, after two chapters of general aspects of interferon action and interaction, selected solid tumours which are commonly considered difficult to treat in advanced stages are discussed with respect to both preclinical data and clinical experience.